| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Division of Pulmonary Sciences and Critical Care Medicine and 2Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado; 3Johns Hopkins University, Baltimore, Maryland; and 4Department of Anatomy, Technical University Dresden, Dresden, Germany
Submitted 21 November 2005 ; accepted in final form 5 May 2006
Severe pulmonary hypertension (SPH) is characterized by precapillary arteriolar lumen obliteration, dramatic right ventricular hypertrophy, and pericardial effusion. Our recently published rat model of SPH recapitulates major components of the human disease. We used this model to develop new treatment strategies for SPH. SPH in rats was induced using VEGF receptor blockade in combination with chronic hypoxia. A large variety of drugs used in this study, including anticancer drugs (cyclophosphamide and paclitaxel), the angiotensin-converting enzyme inhibitor lisinopril, the antiangiogenic agent thalidomide, and the peroxisome proliferator-actived receptor-
agonist PGJ2, failed to decrease mean pulmonary artery pressure (PAP) or right ventricular hypertrophy. In contrast, treatment of rats with established SPH with simvastatin markedly reduced mean PAP and right ventricular hypertrophy, and this reduction was associated with caspase-3 activation and pulmonary microvascular endothelial cell apoptosis. Simvastatin partially restored caveolin-1, caveolin-2, and phospho-caveolin expression in vessel walls. In rat primary pulmonary microvascular endothelial cells, simvastatin induced caspase 3 activation and Rac 1 expression while suppressing Rho A and attenuated levels of Akt and ERK phosphorylation. We conclude that simvastatin is effective in inducing apoptosis in hyperproliferative pulmonary vascular lesions and could be considered as a potential drug for treatment of human SPH.
statins
This article has been cited by other articles:
|
|
 |
|
  N. Homma, T. Nagaoka, V. Karoor, M. Imamura, L. Taraseviciene-Stewart, L. A. Walker, K. A. Fagan, I. F. McMurtry, and M. Oka Involvement of RhoA/Rho kinase signaling in protection against monocrotaline-induced pulmonary hypertension in pneumonectomized rats by dehydroepiandrosterone Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L71 - L78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Wojciak-Stothard New drug targets for pulmonary hypertension: Rho GTPases in pulmonary vascular remodelling Postgrad. Med. J., July 1, 2008; 84(993): 348 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Churg, M. Cosio, and J. L. Wright Mechanisms of cigarette smoke-induced COPD: insights from animal models Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L612 - L631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Korshunov, M. Daul, M. P. Massett, and B. C. Berk Axl Mediates Vascular Remodeling Induced by Deoxycorticosterone Acetate Salt Hypertension Hypertension, December 1, 2007; 50(6): 1057 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Carlin, A. J. Peacock, and D. J. Welsh Fluvastatin Inhibits Hypoxic Proliferation and p38 MAPK Activity in Pulmonary Artery Fibroblasts Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 447 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. McMurtry, S. Bonnet, E. D. Michelakis, S. Bonnet, A. Haromy, and S. L. Archer Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L933 - L940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bauer, T. M. Moore, and I. F. McMurtry Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol, September 1, 2007; 293(3): L580 - L582. [Full Text] [PDF]
|
|
|
|
|
|
M. Li, Y. Liu, P. Dutt, B. L. Fanburg, and D. Toksoz Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin Am J Physiol Lung Cell Mol Physiol, August 1, 2007; 293(2): L463 - L471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Sehgal and S. Mukhopadhyay Dysfunctional Intracellular Trafficking in the Pathobiology of Pulmonary Arterial Hypertension Am. J. Respir. Cell Mol. Biol., July 1, 2007; 37(1): 31 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Sehgal and S. Mukhopadhyay Pulmonary arterial hypertension: a disease of tethers, SNAREs and SNAPs? Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H77 - H85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Sehgal, S. Mukhopadhyay, F. Xu, K. Patel, and M. Shah Dysfunction of Golgi tethers, SNAREs, and SNAPs in monocrotaline-induced pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1526 - L1542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Thebaud and S. H. Abman Bronchopulmonary Dysplasia: Where Have All the Vessels Gone? Roles of Angiogenic Growth Factors in Chronic Lung Disease Am. J. Respir. Crit. Care Med., May 15, 2007; 175(10): 978 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Girgis, S. Mozammel, H. C. Champion, D. Li, X. Peng, L. Shimoda, R. M. Tuder, R. A. Johns, and P. M. Hassoun Regression of chronic hypoxic pulmonary hypertension by simvastatin Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1105 - L1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. McMurtry, R. Moudgil, K. Hashimoto, S. Bonnet, E. D. Michelakis, and S. L. Archer Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L872 - L878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Oka, N. Homma, L. Taraseviciene-Stewart, K. G. Morris, D. Kraskauskas, N. Burns, N. F. Voelkel, and I. F. McMurtry Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats Circ. Res., March 30, 2007; 100(6): 923 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Voelkel, I. S. Douglas, and M. Nicolls Angiogenesis in Chronic Lung Disease Chest, March 1, 2007; 131(3): 874 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Levy, C. Maurey, D. S. Celermajer, P. R. Vouhe, C. Danel, D. Bonnet, and D. Israel-Biet Impaired Apoptosis of Pulmonary Endothelial Cells Is Associated With Intimal Proliferation and Irreversibility of Pulmonary Hypertension in Congenital Heart Disease J. Am. Coll. Cardiol., February 20, 2007; 49(7): 803 - 810. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
